DLBCL — RACP Adult Medicine MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — Non-Hodgkin lymphoma (DLBCL)
Rapidly enlarging lymphadenopathy with B symptoms, elevated LDH, extranodal disease, and biopsy showing diffuse large CD20+ B cells with high proliferation index is DLBCL — the most common aggressive NHL. Treatment is R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) for 6 cycles. Cure rates are 60–70% with R-CHOP.
Reference: ALLG – 2024 – DLBCL; NCCN 2025